The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial release generated massive returns, the lapse of its intellectual property protection opened the floodgates to generic https://friendlybookmark.com/story21516546/sildenafil-and-big-pharma-a-risky-bet